CD274 and non-small cell lung carcinoma: The GFPC-ESCKEYP cohort is a large national multicentric cohort that aims to report real-word data for advanced NSCLC patients with high-level PD-L1 positivity, defined as those with a tumor proportion score (TPS) ≥ 50%, for whom first-line treatment with pembrolizumab as a single agent was initiated.